温中补气方治疗胃癌疗效及对CD3^+、CD4^+、CD4^+/CD8^+变化的研究

Study on Effect of Wenzhong Buqi Prescription on Gastric Cancer and Changes of CD3^+,CD4^+ and CD4^+/CD8^+

目的分析温中补气方对胃癌患者的疗效及T淋巴细胞亚群(CD^+3、CD^+4、CD^+4/CD^+8)的变化研究。方法选取医院于2017年1月—2018年9月收治的100例胃癌患者的临床资料进行分析,分为两组。对照组采用常规治疗,观察组在常规治疗的基础上给予温中补气治疗,分析两组患者治疗后的临床疗效。结果两组患者治疗前中医证候评分组间比较,差异不具有统计学意义(P>0.05)。观察组患者治疗后喜温喜按、胃脘冷痛、空腹痛甚、胃脘饱胀、浮肿、舌苔白滑、手足不温评分低于对照组(P<0.05)。两组患者治疗前低氧诱导因子-1α(HIF-1α)、单核细胞趋化因子-1(MCP-1)、内皮素-1(ET-1)、T淋巴细胞亚群、外周血髓源性抑制细胞(MDSCs)与调节性T细胞(Treg)占外周血单个核细胞比例水平组间比较,差异不具有统计学意义(P>0.05)。观察组患者治疗后CD^+3、CD^+4、CD^+4/CD^+8水平高于对照组,HIF-1α、MCP-1、ET-1、MDSCs与Treg占外周血单个核细胞比例水平低于对照组(P<0.05)。结论温中补气方治疗胃癌,可改善患者的中医证候,降低HIF-1α、MCP-1、ET-1水平,调节MDSCs与Treg占外周血单个核细胞比例。

Objective To analyze the effect of Wenzhong Buqi Prescription on gastric cancer patients and the changes of T lymphocyte subgroup(CD^+3,CD^+4,CD^+4/CD^+8).Methods The clinical data of 100 cases of gastric cancer patients admitted and treated from January 2017 to September 2018 was selected for analysis.The patients were divided into two groups.The control group was treated with conventional treatment,and the observation group was given warming the middle and supplementing Qi treatment on the basis of conventional treatment,and the clinical efficacy of the two groups was analyzed after treatment.Results Before treatment,there was no statistically significant difference in TCM syndrome evaluation between the two groups(P>0.05).After treatment,the observation group’s scores of preferring warm and pressing,epigastric cold pain,empty abdominal pain,epigastric fullness and edema,white tongue coating and cold hands and feet were less than those in the control group(P<0.05).Two groups’alpha HIF-1α(HIF-1α),monocyte chemotactic factor 1(MCP-1),endothelin 1(ET-1),T lymphocyte subgroup,peripheral blood marrow source sex suppression cells(MDSCs)and regulatory T cells(Treg)of peripheral blood mononuclear cell percentage had no statistically significant difference(P>0.05).After treatment,levels of CD^+3,CD^+4 and CD^+4/CD^+8 in the observation group were higher than those in the control group,and the proportions of HIF-1α,MCP-1,ET-1,MDSCs and Treg in peripheral blood mononuclear cells were lower than those in the control group(P<0.05).Conclusion In the treatment of gastric cancer,Wenzhong Buqi Prescription can improve the TCM syndromes of patients,reduce the levels of HIF-1α,MCP-1,ET-1,and regulate the proportions of MDSCs and Treg in peripheral blood mononuclear cells.